Welcome to our dedicated page for Guardian Pharmacy Services SEC filings (Ticker: GRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardian Pharmacy Services, Inc. filings document the reporting obligations of a NYSE-listed long-term care pharmacy services company with Class A common stock. Recent Form 8-K filings furnish operating results, financial guidance, investor presentation materials, and exhibits tied to the company’s pharmacy services business.
Proxy and current-report filings also cover board elections, advisory compensation votes, stockholder voting results, material stock purchase agreements, lock-up arrangements, and conversion-related disclosures involving Class A and Class B common stock. These records describe governance, ownership, capital-structure mechanics, registered securities, and matters linked to the company’s September 2024 corporate reorganization.
Guardian Pharmacy Services, Inc. (GRDN) entered into lock-up agreements effective September 10, 2026 with its founders, executive officers and certain other employees covering their Class A common stock. After an automatic conversion of 13,521,396 shares of Class B common stock into Class A common stock on September 27, 2026, approximately 29.9 million shares of Class A common stock held by these holders will be subject to the lock-up.
The locked-up shares represent about 81% of roughly 37 million Class A shares that will be held by all founders, executive officers and other pre-IPO employees. Subject to limited exceptions and without the Company’s prior consent, these shares cannot be offered, sold, distributed, disposed of or transferred through September 14, 2027. Following the September 27, 2026 conversion, the Company will have 63,320,300 shares of Class A common stock outstanding.
Guardian Pharmacy Services, Inc. reported solid growth for the three and six months ended June 30, 2026. Q2 2026 revenue was $351,768 (in thousands), up 2.2% year over year, while net income attributable to the company rose to $21,872 (in thousands) from $9,030 (in thousands). Diluted EPS increased to $0.34 from $0.14. Adjusted EBITDA for Q2 grew to $29,658 (in thousands), or 8.4% of revenue.
Results were shaped by 2025 acquisitions and U.S. Inflation Reduction Act (IRA) drug pricing, which reduced organic revenue but more sharply lowered product costs, improving gross margin from 19.8% to 22.8%. Residents served increased from 195,000 to 210,000, and Q2 prescriptions dispensed rose from 7.0 million to 7.6 million.
The company recorded an $8.5 million cash gain from a payor-reimbursement settlement, boosting other income. Liquidity remained strong with $89,807 (in thousands) of cash and cash equivalents and no borrowings outstanding on a $40 million revolving credit facility that now matures in 2030, with the option to expand total capacity to $80 million.
Guardian Pharmacy Services reported Q2 2026 revenue of $351,768 thousand compared with $344,334 thousand a year earlier, as IRA‑related pricing reductions muted reported growth. Net income attributable to the company was $21,872 thousand, diluted EPS was $0.34, and Adjusted EBITDA was $29,658 thousand, or 8.4% of revenue. Results included an $8.5 million cash settlement related to a payor‑reimbursement matter, recorded in other income.
Cash and cash equivalents rose to $89,807 thousand at June 30, 2026, with total assets of $443,578 thousand. Based on year‑to‑date performance, management raised its 2026 outlook to revenue of $1.43 billion–$1.45 billion and Adjusted EBITDA of $129 million–$131 million, excluding future acquisitions. Guardian also acquired Wellness Concepts in Virginia, opened a greenfield pharmacy in Lexington, Kentucky, and implemented new COO/CFO appointments and a regional leadership structure.
Guardian Pharmacy Services, Inc. announced a set of leadership transitions centered on the planned retirement of Executive Vice President of Sales & Operations Kendall Forbes, effective July 1, 2026. Forbes will remain as an employee through August 31, 2026 to help transition his responsibilities.
On July 1, 2026, David Morris will move from Executive Vice President and Chief Financial Officer to Executive Vice President and Chief Operating Officer, while Will Mudd, currently Senior Vice President, Finance, will become Senior Vice President and Chief Financial Officer. The company highlights these internal promotions as part of its succession planning and notes that Mudd’s compensation will remain aligned with other executives, with no additional pay tied to his promotion.
Guardian describes itself as a long-term care pharmacy services provider with 61 licensed pharmacies, including 54 full-service locations, serving approximately 207,000 residents as of March 31, 2026.
Guardian Pharmacy Services, Inc. amended its senior credit facility, entering into an Eighth Amendment to its Third Amended and Restated Loan and Security Agreement. The amendment extends the maturity of the revolving loan commitments from April 23, 2027 to May 21, 2030 and allows incremental term loans or additional revolver capacity up to $40 million, which could bring total borrowing capacity to $80 million.
The amendment also replaces the borrower entity name with the public company, increases certain baskets and thresholds, and changes the financial covenant from a consolidated leverage ratio to a consolidated net leverage ratio. Net leverage will be calculated as consolidated debt minus up to $20 million of unrestricted cash, divided by consolidated Adjusted EBITDA.
COSLER STEVEN D reported acquisition or exercise transactions in this Form 4 filing.
Guardian Pharmacy Services, Inc. director Steven D. Cosler received an equity grant of 4,028 shares of Class A common stock in the form of restricted stock units, awarded at no cash cost per share.
After this grant, Cosler directly holds 29,012 Class A common shares, reflecting a routine compensation-related award rather than an open-market purchase or sale.
Guardian Pharmacy Services director LEWIS RANDALL J received an equity grant of 4,028 shares of Class A common stock on May 5, 2026. The award is structured as restricted stock units payable solely in shares of Class A common stock and carries no cash exercise price.
After this grant, the director holds 15,071 shares directly. This is a compensation-related award rather than an open-market purchase or sale, so it reflects routine equity-based compensation rather than a trading decision.
Patchett Mary Sue reported acquisition or exercise transactions in this Form 4 filing.
Guardian Pharmacy Services, Inc. director Mary Sue Patchett received an equity grant of 4,028 shares of Class A Common Stock at a price of $0.00 per share. This award is in the form of restricted stock units that will be paid solely in Class A shares. After this grant, she directly holds 15,071 shares, showing her total reported equity stake following the award.
Guardian Pharmacy Services, Inc. reported results from its 2026 Annual Meeting of Stockholders held on May 5, 2026. Stockholders elected Class II directors John Ackerman and Randall Lewis to terms running until the 2029 annual meeting.
Both nominees received over 44.6 million votes "for," with additional broker non-votes recorded. Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and selected a one-year frequency for future advisory votes on executive pay. In addition, stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026.
Guardian Pharmacy Services, Inc. filed an automatic shelf registration statement to permit the offering, issuance and resale of its Class A common stock from time to time after effectiveness. The prospectus also contemplates resales by identified selling stockholders; the company states it will not receive proceeds from shares sold by those selling stockholders.
The prospectus describes the company, its business serving approximately 207,000 residents through 61 pharmacies (54 full-service) across 38 states as of March 31, 2026, and discloses capital structure and transfer/conversion features of Class A and Class B common stock.